Introduction
Malignant ovarian germ cell tumors (MOGCTs) usually occur in young women, 1 and they account for 1e2% of all ovarian malignancies. 2 Until the 1970s, before establishment of systemic chemotherapy, MOGCTs had a very poor prognosis. However, after the introduction of chemotherapy consisting of bleomycin, etoposide, and cisplatin (BEP) for MOGCT treatment, the prognosis dramatically improved. 3 Moreover, as BEP therapy has little effect on ovarian function, most MOGCT patients treated with BEP were able to remain fertile and give birth. 4e16 However, the number of MOGCT survivors who actually became pregnant remains unknown, as there is a relatively long period from MOGCT treatment to pregnancy because age at first marriage or childbirth is increasing, especially in Japan. 17 The present study aimed to clarify the reproductive outcomes in MOGCT survivors by using data from a multicenter database and an additional survey on reproductive outcomes.
Materials and Methods
The Tokai Ovarian Tumor Study Group includes Nagoya University Hospital and 13 other institutions, and its database has been collecting ovarian cancer patient data since 1986, with approval from our ethics committee. All surgical specimens were pathologically reviewed by specialist gynecological pathologists blinded to the clinical data of patients. We screened the database from 1986 through 2016 and selected MOGCT patients <40 years of age. We further identified patients who underwent fertility-sparing treatment (FST). In this study, FST was defined as preservation of the uterus and at least 1 ovary during surgery with any chemotherapy regimen but without adjuvant radiation therapy to the entire pelvis. To obtain additional data on MOGCT patients who underwent FST, questionnaires on reproductive outcomes were sent to the registered facilities in December 2016, and all completed questionnaires were collected. The following data were collected and used in this study: age, date of onset, surgical procedure, chemotherapy regimen, tumor type, International Federation of Gynecology and Obstetrics (FIGO) stage, survival outcome and period, number of pregnancies and childbirths, marital status, childbearing desire, method of pregnancy, gestational weeks at delivery, birthweight of the baby, obstetrical complications, and menstrual status after FST. (Figure 1) .
The menstrual status after FST is summarized in Table 2 . Regular menstruation recovered in 57 of 72 patients who received adjuvant chemotherapy. The median time to menstruation recovery was 6 months. At the time of the additional survey, 3 patients had premature ovarian failure at <40 years of age. The characteristics of these 3 patients are summarized in Table 3 .
The obstetric outcomes after FST are summarized in Table 4 . Among the 105 survivors, 45 attempted to become pregnant. Of these 45 patients, 42 achieved pregnancy, and 40 patients had successful deliveries. Seven patients received infertility treatment, but only 2 patients needed assisted reproductive technology.
AJOG at a Glance
Why was this study conducted? To describe the reproductive outcomes of survivors of malignant ovarian germ cell tumor (MOGCT).
Key findings
Over 90% of survivors of MOGCT <40 years of age who received fertility-sparing treatment and desired pregnancy became pregnant and gave birth.
What does this add to what is known?
This study demonstrated favorable reproductive outcomes for survivors of MOGCT, including women with advanced stage diagnoses. (Tables 5 and 6 ).
Supplementary Figure 1 is a scatter plot showing the relationship between onset and pregnancy period. The horizontal axis shows the MOGCT onset age, and the vertical axis shows the period from surgery to first child delivery. Together, Supplementary Figure 2 and Table 3 indicate that the important factor related to the duration to achieving pregnancy was not adjuvant chemotherapy but marital status at FST.
Comment
MOGCTs occur in young women, and it is now possible to achieve cure and fertility preservation; therefore, reproductive outcomes are considered important. However, there are sporadic reports on reproductive outcomes in MOGCT survivors.
4e16 This is because MOGCT is a relatively rare cancer, and only about 30 years have passed since the dramatic improvement in prognosis with BEP therapy. Furthermore, there is usually a gap of >5 years between onset age and pregnancy age ( Supplementary  Figure 2) , making it difficult to accumulate data on pregnancy outcomes in survivors. In this study, we assessed the reproductive outcomes of 105 survivors after assessing >5000 patients included in a database over a period of 30 years. To our knowledge, this study included the largest number of MOGCT patients in whom reproductive outcomes were examined.
In this study, >90% of the 45 survivors who desired to bear children became pregnant. Most patients lost 1 ovary because of surgery and received adjuvant chemotherapy, but these did not cause much disadvantage in terms of pregnancy, as reported previously. With regard to the effect on long-term ovarian function, 3 cases of premature ajog.org GYNECOLOGY Original Research menopause age of <40 years were recorded. However, as the median age at the time of additional survey was 33.5 years, this finding is difficult to discuss. In MOGCT patients, the influence of chemotherapy on long-term ovarian function requires further investigation. Although MOGCT is expected to be curable with BEP therapy, this therapy is not easy. Cisplatin has a high risk for chemotherapy-induced nausea and vomiting. 18 In addition, BEP therapy is associated with several adverse effects, such as neutropenia and fever. 19, 20 In young women, depilation by etoposide and bleomycin is an anxious side effect. Low-dose intensity and compliance with the administration schedule have been reported to affect prognosis; thus, the treatment should not be changed or delayed due to temporary side effects. 21 In MOGCT patients, in addition to a desire for cure, a desire to become pregnant in the future may improve treatment compliance, as shown in the present study.
In previous studies, it was shown that FST did not affect cancer prognosis in patients with advanced-stage MOGCTs. 8, 10, 16, 22, 23 However, the numbers of pregnancies and childbirths after FST for advanced MOGCTs were unclear. In the present study, 8 of 40 patients with successful deliveries had FIGO stage II or III MOGCTs. Taken together, these findings suggest that it is not necessary to give up fertility preservation because of advanced tumor stage at diagnosis. Moreover, 2 patients gave birth after tumor recurrence. Thus, the possibility of fertility preservation at the time of recurrence can be explored.
The present study has several limitations. This was a retrospective, multicenter study; thus, there might be differences in the details of surgery and chemotherapies. Additionally, this study did not include pediatric MOGCT patients, as the assessed database registered only patients treated at gynecological facilities. Moreover, as the median patient age at the additional survey was 33.5 years, the numbers of pregnancies and childbirths were not stable. Furthermore, the effects of FST on ovarian function might manifest later in life. In conclusion, we showed that MOGCT survivors could become pregnant and give birth if they desire. Advanced tumor stage or recurrence should not be used as indicators for avoiding fertility preservation. We believe that the results of the present study will encourage patients to overcome MOGCTs with FST. n
